BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34862398)

  • 1. MVA vector expression of SARS-CoV-2 spike protein and protection of adult Syrian hamsters against SARS-CoV-2 challenge.
    Meseda CA; Stauft CB; Selvaraj P; Lien CZ; Pedro C; Nuñez IA; Woerner AM; Wang TT; Weir JP
    NPJ Vaccines; 2021 Dec; 6(1):145. PubMed ID: 34862398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice.
    García-Arriaza J; Garaigorta U; Pérez P; Lázaro-Frías A; Zamora C; Gastaminza P; Del Fresno C; Casasnovas JM; Sorzano CÓS; Sancho D; Esteban M
    J Virol; 2021 Mar; 95(7):. PubMed ID: 33414159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters.
    Abdelnabi R; Pérez P; Astorgano D; Albericio G; Kerstens W; Thibaut HJ; Coelmont L; Weynand B; Labiod N; Delgado R; Montenegro D; Puentes E; Rodríguez E; Neyts J; Dallmeier K; Esteban M; García-Arriaza J
    Front Immunol; 2023; 14():1163159. PubMed ID: 37920464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters.
    Boudewijns R; Pérez P; Lázaro-Frías A; Van Looveren D; Vercruysse T; Thibaut HJ; Weynand B; Coelmont L; Neyts J; Astorgano D; Montenegro D; Puentes E; Rodríguez E; Dallmeier K; Esteban M; García-Arriaza J
    Front Immunol; 2022; 13():845969. PubMed ID: 35371064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.
    Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2022; 13():995235. PubMed ID: 36172368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates.
    Pérez P; Albericio G; Astorgano D; Flores S; Sánchez-Corzo C; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2023; 14():1264323. PubMed ID: 38155964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity.
    Meyer Zu Natrup C; Tscherne A; Dahlke C; Ciurkiewicz M; Shin DL; Fathi A; Rohde C; Kalodimou G; Halwe S; Limpinsel L; Schwarz JH; Klug M; Esen M; Schneiderhan-Marra N; Dulovic A; Kupke A; Brosinski K; Clever S; Schünemann LM; Beythien G; Armando F; Mayer L; Weskamm ML; Jany S; Freudenstein A; Tuchel T; Baumgärtner W; Kremsner P; Fendel R; Addo MM; Becker S; Sutter G; Volz A
    J Clin Invest; 2022 Dec; 132(24):. PubMed ID: 36301637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Live-attenuated pediatric parainfluenza vaccine expressing 6P-stabilized SARS-CoV-2 spike protein is protective against SARS-CoV-2 variants in hamsters.
    Liu X; Park HS; Matsuoka Y; Santos C; Yang L; Luongo C; Moore IN; Johnson RF; Garza NL; Zhang P; Lusso P; Best SM; Buchholz UJ; Le Nouën C
    bioRxiv; 2022 Dec; ():. PubMed ID: 36561185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poxvirus MVA Expressing SARS-CoV-2 S Protein Induces Robust Immunity and Protects Rhesus Macaques From SARS-CoV-2.
    Mooij P; García-Arriaza J; Pérez P; Lázaro-Frías A; Verstrepen BE; Böszörményi KP; Mortier D; Fagrouch Z; Kiemenyi-Kayere G; Niphuis H; Acar RF; Meijer L; Stammes MA; Kondova I; Verschoor EJ; GeurtsvanKessel CH; de Bruin E; Sikkema RS; Luczkowiak J; Delgado R; Montenegro D; Puentes E; Rodríguez E; Bogers WMJM; Koopman G; Esteban M
    Front Immunol; 2022; 13():845887. PubMed ID: 35371043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination.
    Tscherne A; Schwarz JH; Rohde C; Kupke A; Kalodimou G; Limpinsel L; Okba NMA; Bošnjak B; Sandrock I; Odak I; Halwe S; Sauerhering L; Brosinski K; Liangliang N; Duell E; Jany S; Freudenstein A; Schmidt J; Werner A; Gellhorn Serra M; Klüver M; Guggemos W; Seilmaier M; Wendtner CM; Förster R; Haagmans BL; Becker S; Sutter G; Volz A
    Proc Natl Acad Sci U S A; 2021 Jul; 118(28):. PubMed ID: 34162739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and efficacy of a novel multi-patch SARS-CoV-2/COVID-19 vaccine candidate.
    Perdiguero B; Marcos-Villar L; López-Bravo M; Sánchez-Cordón PJ; Zamora C; Valverde JR; Sorzano CÓS; Sin L; Álvarez E; Ramos M; Del Val M; Esteban M; Gómez CE
    Front Immunol; 2023; 14():1160065. PubMed ID: 37404819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung transcriptomics of K18-hACE2 mice highlights mechanisms and genes involved in the MVA-S vaccine-mediated immune response and protection against SARS-CoV-2 infection.
    Gómez-Carballa A; Albericio G; Montoto-Louzao J; Pérez P; Astorgano D; Rivero-Calle I; Martinón-Torres F; Esteban M; Salas A; García-Arriaza J
    Antiviral Res; 2023 Dec; 220():105760. PubMed ID: 37992765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters.
    Su W; Sia SF; Schmitz AJ; Bricker TL; Starr TN; Greaney AJ; Turner JS; Mohammed BM; Liu Z; Choy KT; Darling TL; Joshi A; Cheng KM; Wong AYL; Harastani HH; Nicholls JM; Whelan SPJ; Bloom JD; Yen HL; Ellebedy AH; Boon ACM
    mBio; 2021 Oct; 12(5):e0239521. PubMed ID: 34517754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccinia Virus Strain MVA Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Glycoprotein Induces Robust Protection and Prevents Brain Infection in Mouse and Hamster Models.
    Lorenzo MM; Marín-López A; Chiem K; Jimenez-Cabello L; Ullah I; Utrilla-Trigo S; Calvo-Pinilla E; Lorenzo G; Moreno S; Ye C; Park JG; Matía A; Brun A; Sánchez-Puig JM; Nogales A; Mothes W; Uchil PD; Kumar P; Ortego J; Fikrig E; Martinez-Sobrido L; Blasco R
    Vaccines (Basel); 2023 May; 11(5):. PubMed ID: 37243110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of Toll-like receptor agonists on the immunogenicity of MVA-SARS-2-S vaccine after intranasal administration in mice.
    Do KTH; Willenzon S; Ristenpart J; Janssen A; Volz A; Sutter G; Förster R; Bošnjak B
    Front Cell Infect Microbiol; 2023; 13():1259822. PubMed ID: 37854858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trimerized S expressed by modified vaccinia virus Ankara (MVA) confers superior protection against lethal SARS-CoV-2 challenge in mice.
    Zhu J; Wang Z; Li Y; Zhang Z; Ren S; Wang J; Xie S; Liao Z; Song B; Wu W; Yan F; Peng C
    J Virol; 2024 Jun; ():e0052124. PubMed ID: 38874361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single intranasal or intramuscular immunization with chimpanzee adenovirus vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters.
    Bricker TL; Darling TL; Hassan AO; Harastani HH; Soung A; Jiang X; Dai YN; Zhao H; Adams LJ; Holtzman MJ; Bailey AL; Case JB; Fremont DH; Klein R; Diamond MS; Boon ACM
    bioRxiv; 2020 Dec; ():. PubMed ID: 33299991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection.
    Li M; Guo J; Lu S; Zhou R; Shi H; Shi X; Cheng L; Liang Q; Liu H; Wang P; Wang N; Wang Y; Fu L; Xing M; Wang R; Ju B; Liu L; Lau SY; Jia W; Tong X; Yuan L; Guo Y; Qi H; Zhang Q; Huang Z; Chen H; Zhang Z; Chen Z; Peng X; Zhou D; Zhang L
    Front Immunol; 2021; 12():697074. PubMed ID: 34262569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Cold-Adapted, Temperature-Sensitive SARS-CoV-2 Strain TS11 Is Attenuated in Syrian Hamsters and a Candidate Attenuated Vaccine.
    Xu J; Liu M; Niu X; Hanson J; Jung K; Ru P; Tu H; Jones DM; Vlasova AN; Saif LJ; Wang Q
    Viruses; 2022 Dec; 15(1):. PubMed ID: 36680135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal or airborne transmission-mediated delivery of an attenuated SARS-CoV-2 protects Syrian hamsters against new variants.
    Stauft CB; Selvaraj P; D'Agnillo F; Meseda CA; Liu S; Pedro CL; Sangare K; Lien CZ; Weir JP; Starost MF; Wang TT
    Nat Commun; 2023 Jun; 14(1):3393. PubMed ID: 37296125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.